person · Reporting owner

Redfield Robert

Disclosed activity across 1 company

Tapewire entity: 30608
SEC CIK: 0002018274

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Traws Pharma, Inc.TRAW · Entity 8032	Chief Medical Officer	July 09, 2026	July 15, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Traws Pharma, Inc.

Report date July 09, 2026 · Filed July 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.68 · Expires 2036-07-09	Direct	84,000	Reported balance After 2026-07-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-07-09 · Grant · Acquired 84,000 · Balance 84,000 F1: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 09, 2026 Filed Jul 15, 2026 00:23 UTC	Traws Pharma, Inc. TRAW · Entity 8032	GrantStock Option (right to buy) · Derivative	84,000	$0.00 Strike: $0.68	$0.00	Disclosure SEC source: 0002018274-26-000003 · form4-07152026_120748.xml · derivative · entry 1 Redfield Robert · CIK 0002018274 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,000 Underlying: Common Stock · 84,000 shares Expires 2036-07-09 F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date. Read SEC document
March 08, 2026 Filed Mar 10, 2026 23:15 UTC	Traws Pharma, Inc. TRAW · Entity 8032	GrantStock Option (right to buy) · Derivative	108,854	$0.00 Strike: $1.60	$0.00	Disclosure SEC source: 0002018274-26-000002 · form4-03102026_110357.xml · derivative · entry 1 Redfield Robert · CIK 0002018274 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,854 Underlying: Common Stock · 108,854 shares Expires 2036-03-08 F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date. Read SEC document
December 12, 2025 Filed Dec 16, 2025 23:15 UTC	Traws Pharma, Inc. TRAW · Entity 8032	GrantStock Option (right to purchase) · Derivative	65,676	$0.00 Strike: $2.33	$0.00	Disclosure SEC source: 0002018274-25-000004 · form4-12162025_111226.xml · derivative · entry 2 Redfield Robert · CIK 0002018274 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,676 Underlying: Common Stock · 65,676 shares Expires 2035-12-12 F2 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date. Read SEC document
December 12, 2025 Filed Dec 16, 2025 23:15 UTC	Traws Pharma, Inc. TRAW · Entity 8032	GrantCommon Stock	16,419	$0.00	$0.00	Disclosure SEC source: 0002018274-25-000004 · form4-12162025_111226.xml · nonDerivative · entry 1 Redfield Robert · CIK 0002018274 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,919 F1 · shares: Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis. Read SEC document
October 12, 2025 Filed Oct 16, 2025 00:09 UTC	Traws Pharma, Inc. TRAW · Entity 8032	GrantStock Option (right to purchase) · Derivative	32,406	$0.00 Strike: $3.01	$0.00	Disclosure SEC source: 0002018274-25-000003 · form4-10162025_121036.xml · derivative · entry 1 Redfield Robert · CIK 0002018274 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,406 Underlying: Common Stock · 32,406 shares Expires 2035-10-12 F1 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date. Read SEC document
April 01, 2024 Filed Apr 4, 2024 00:07 UTC	Traws Pharma, Inc. TRAW · Entity 8032	GrantCommon Stock	97,500	Not disclosed	Not disclosed	Disclosure SEC source: 0000929638-24-001366 · form4.xml · nonDerivative · entry 1 Redfield Robert · CIK 0002018274 · Acting Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,500 F1 · price: Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025. Each restricted stock unit will convert into common stock of Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc.), par value $0.01 per share, on a one-for-one basis. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.